Aron S Buchman1,2, Lei Yu1,2, Shahram Oveisgharan1,2, Jose M Farfel1,3, Julie A Schneider1,3, David A Bennett1,2. 1. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois. 2. Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois. 3. Department of Pathology, Rush University Medical Center, Chicago, Illinois.
Abstract
BACKGROUND: Mixed-brain pathologies are the most common cause of progressive parkinsonism in older adults. We tested the hypothesis that the impact of individual pathologies associated with progressive parkinsonism differs among older adults. METHODS: Data were from 1089 decedents who had undergone annual clinical testing and autopsy. Parkinsonism was based on a modified United Parkinson's Disease Rating Scale. Linear mixed-effects models were employed, to investigate the combinations of 9 pathologies related to progressive parkinsonism. Then we estimated the person-specific contributions of each pathology for progressive parkinsonism. RESULTS: The average participant showed 3 pathologies. Parkinson's disease (PD) and 4 cerebrovascular pathologies (macroinfarcts, atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy [CAA]), but not Alzheimer's disease, TDP-43, hippocampal sclerosis, and microinfarcts, were independently associated with progressive parkinsonism. These pathologies accounted for 13% of additional variance of progressive parkinsonism. Thirty-one different combinations of these 5 pathologies were observed to be associated with progressive parkinsonism observed. On average, PD and CAA accounted, respectively, for 66% and 65% of person-specific progression of parkinsonism, while macroinfarcts, atherosclerosis, and arteriolosclerosis accounted for 41%-48%. CONCLUSION: There is much greater heterogeneity in the comorbidity and relative impact of individual brain pathologies affecting progressive parkinsonism than previously recognized and this may account in part for its phenotypic heterogeneity in older adults.
BACKGROUND: Mixed-brain pathologies are the most common cause of progressive parkinsonism in older adults. We tested the hypothesis that the impact of individual pathologies associated with progressive parkinsonism differs among older adults. METHODS: Data were from 1089 decedents who had undergone annual clinical testing and autopsy. Parkinsonism was based on a modified United Parkinson's Disease Rating Scale. Linear mixed-effects models were employed, to investigate the combinations of 9 pathologies related to progressive parkinsonism. Then we estimated the person-specific contributions of each pathology for progressive parkinsonism. RESULTS: The average participant showed 3 pathologies. Parkinson's disease (PD) and 4 cerebrovascular pathologies (macroinfarcts, atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy [CAA]), but not Alzheimer's disease, TDP-43, hippocampal sclerosis, and microinfarcts, were independently associated with progressive parkinsonism. These pathologies accounted for 13% of additional variance of progressive parkinsonism. Thirty-one different combinations of these 5 pathologies were observed to be associated with progressive parkinsonism observed. On average, PD and CAA accounted, respectively, for 66% and 65% of person-specific progression of parkinsonism, while macroinfarcts, atherosclerosis, and arteriolosclerosis accounted for 41%-48%. CONCLUSION: There is much greater heterogeneity in the comorbidity and relative impact of individual brain pathologies affecting progressive parkinsonism than previously recognized and this may account in part for its phenotypic heterogeneity in older adults.
Authors: Patricia A Boyle; Jingyun Yang; Lei Yu; Sue E Leurgans; Ana W Capuano; Julie A Schneider; Robert S Wilson; David A Bennett Journal: Brain Date: 2017-03-01 Impact factor: 13.501
Authors: Lisa L Barnes; Raj C Shah; Neelum T Aggarwal; David A Bennett; Julie A Schneider Journal: Curr Alzheimer Res Date: 2012-07 Impact factor: 3.498
Authors: Aron S Buchman; Sue E Leurgans; Sukriti Nag; Veronique G J M VanderHorst; Alifiya Kapasi; Julie A Schneider; David A Bennett Journal: Stroke Date: 2017-09-20 Impact factor: 7.914
Authors: Aron S Buchman; R S Wilson; Joshua M Shulman; Sue E Leurgans; Julie A Schneider; David A Bennett Journal: J Gerontol A Biol Sci Med Sci Date: 2015-09-10 Impact factor: 6.053
Authors: Patricia A Boyle; Lei Yu; Robert S Wilson; Sue E Leurgans; Julie A Schneider; David A Bennett Journal: Ann Neurol Date: 2018-01-14 Impact factor: 10.422
Authors: David A Bennett; Aron S Buchman; Patricia A Boyle; Lisa L Barnes; Robert S Wilson; Julie A Schneider Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Aron S Buchman; Lei Yu; Robert S Wilson; Sue E Leurgans; Sukriti Nag; Joshua M Shulman; Lisa L Barnes; Julie A Schneider; David A Bennett Journal: Neurology Date: 2019-03-20 Impact factor: 9.910
Authors: Aron S Buchman; Tianhao Wang; Lei Yu; Sue E Leurgans; Julie A Schneider; David A Bennett Journal: Acta Neuropathol Date: 2020-08-14 Impact factor: 17.088
Authors: Meagan Bailey; Lisa M Shulman; Diane Ryan; Bichun Ouyang; Joshua M Shulman; Aron S Buchman; David A Bennett; Lisa L Barnes; Deborah A Hall Journal: J Gerontol A Biol Sci Med Sci Date: 2021-06-14 Impact factor: 6.053
Authors: Sukriti Nag; Lisa L Barnes; Lei Yu; Aron S Buchman; David A Bennett; Julie A Schneider; Robert S Wilson Journal: Neurology Date: 2021-06-04 Impact factor: 11.800
Authors: Shahram Oveisgharan; Ana W Capuano; Sukriti Nag; Sonal Agrawal; Lisa L Barnes; David A Bennett; Zoe Arvanitakis; Julie A Schneider Journal: Neurology Date: 2021-04-14 Impact factor: 11.800
Authors: Shahram Oveisgharan; Lei Yu; Lisa L Barnes; Sonal Agrawal; Julie A Schneider; David A Bennett; Aron S Buchman Journal: Neurology Date: 2022-03-23 Impact factor: 11.800
Authors: Aron S Buchman; Sue E Leurgans; Tianhao Wang; Michal Schnaider-Beeri; Puja Agarwal; Robert J Dawe; Osvaldo Delbono; David A Bennett Journal: PLoS One Date: 2021-02-02 Impact factor: 3.240